Indian API manufacturing sector buoyant but multinational players likely to be hit by new Drug Price Control Order

摘要

Indian pharma companies filed 417 Drug Master Files (DMFs) with the US FDA during 2012 compared with 404 in the previous year. The number of DMF filings in 2010 and 2009 were 311 and 271 respectively. This clearly shows that the API segment in India is intent on spreading its wings in markets with higher filings. India remains one of most favoured API destinations globally. Despite several adverse factors like stiff competition, the slowdown in the world economy, cost cutting measures in highly regulated markets and unfavourable foreign exchange rates, Indian API players have dominated market share after their Chinese counterparts.